113 related articles for article (PubMed ID: 7779082)
1. Potent inhibitors of the HIV-1 protease with good oral bioavailabilities.
Sham HL; Zhao C; Marsh KC; Betebenner DA; Lin S; McDonald E; Vasavanonda S; Wideburg N; Saldivar A; Robins T
Biochem Biophys Res Commun; 1995 Jun; 211(1):159-65. PubMed ID: 7779082
[TBL] [Abstract][Full Text] [Related]
2. Novel azacyclic ureas that are potent inhibitors of HIV-1 protease.
Sham HL; Zhao C; Marsh KC; Betebenner DA; Lin S; Rosenbrook W; Herrin T; Li L; Madigan D; Vasavanonda S; Molla A; Saldivar A; McDonald E; Wideburg NE; Kempf D; Norbeck DW; Plattner JJ
Biochem Biophys Res Commun; 1996 Aug; 225(2):436-40. PubMed ID: 8753780
[TBL] [Abstract][Full Text] [Related]
3. Potent HIV protease inhibitors containing a novel (hydroxyethyl)amide isostere.
Beaulieu PL; Wernic D; Abraham A; Anderson PC; Bogri T; Bousquet Y; Croteau G; Guse I; Lamarre D; Liard F; Paris W; Thibeault D; Pav S; Tong L
J Med Chem; 1997 Jul; 40(14):2164-76. PubMed ID: 9216835
[TBL] [Abstract][Full Text] [Related]
4. L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor.
Dorsey BD; Levin RB; McDaniel SL; Vacca JP; Guare JP; Darke PL; Zugay JA; Emini EA; Schleif WA; Quintero JC
J Med Chem; 1994 Oct; 37(21):3443-51. PubMed ID: 7932573
[TBL] [Abstract][Full Text] [Related]
5. Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease.
Kaldor SW; Kalish VJ; Davies JF; Shetty BV; Fritz JE; Appelt K; Burgess JA; Campanale KM; Chirgadze NY; Clawson DK; Dressman BA; Hatch SD; Khalil DA; Kosa MB; Lubbehusen PP; Muesing MA; Patick AK; Reich SH; Su KS; Tatlock JH
J Med Chem; 1997 Nov; 40(24):3979-85. PubMed ID: 9397180
[TBL] [Abstract][Full Text] [Related]
6. Pseudo-symmetrical difluoroketones. Highly potent and specific inhibitors of HIV-1 protease.
Sham HL; Betebenner DA; Wideburg N; Saldivar AC; Kohlbrenner WE; Craig-Kennard A; Vasavanonda S; Kempf DJ; Clement JJ; Erickson JE
FEBS Lett; 1993 Aug; 329(1-2):144-6. PubMed ID: 8354389
[TBL] [Abstract][Full Text] [Related]
7. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans.
Kempf DJ; Marsh KC; Denissen JF; McDonald E; Vasavanonda S; Flentge CA; Green BE; Fino L; Park CH; Kong XP
Proc Natl Acad Sci U S A; 1995 Mar; 92(7):2484-8. PubMed ID: 7708670
[TBL] [Abstract][Full Text] [Related]
8. The synthesis of symmetrical and unsymmetrical P1/P1' cyclic ureas as HIV protease inhibitors.
Patel M; Kaltenbach RF; Nugiel DA; McHugh RJ; Jadhav PK; Bacheler LT; Cordova BC; Klabe RM; Erickson-Viitanen S; Garber S; Reid C; Seitz SP
Bioorg Med Chem Lett; 1998 May; 8(9):1077-82. PubMed ID: 9871711
[TBL] [Abstract][Full Text] [Related]
9. Potent human immunodeficiency virus type 1 protease inhibitors that utilize noncoded D-amino acids as P2/P3 ligands.
Jungheim LN; Shepherd TA; Baxter AJ; Burgess J; Hatch SD; Lubbehusen P; Wiskerchen M; Muesing MA
J Med Chem; 1996 Jan; 39(1):96-108. PubMed ID: 8568831
[TBL] [Abstract][Full Text] [Related]
10. Discovery of novel benzothiazolesulfonamides as potent inhibitors of HIV-1 protease.
Nagarajan SR; De Crescenzo GA; Getman DP; Lu HF; Sikorski JA; Walker JL; McDonald JJ; Houseman KA; Kocan GP; Kishore N; Mehta PP; Funkes-Shippy CL; Blystone L
Bioorg Med Chem; 2003 Nov; 11(22):4769-77. PubMed ID: 14556792
[TBL] [Abstract][Full Text] [Related]
11. A series of penicillin derived C2-symmetric inhibitors of HIV-1 proteinase: synthesis, mode of interaction, and structure-activity relationships.
Humber DC; Bamford MJ; Bethell RC; Cammack N; Cobley K; Evans DN; Gray NM; Hann MM; Orr DC; Saunders J
J Med Chem; 1993 Oct; 36(21):3120-8. PubMed ID: 8230098
[TBL] [Abstract][Full Text] [Related]
12. Aminodiol HIV protease inhibitors. 1. Design, synthesis, and preliminary SAR.
Barrish JC; Gordon E; Alam M; Lin PF; Bisacchi GS; Chen P; Cheng PT; Fritz AW; Greytok JA; Hermsmeier MA
J Med Chem; 1994 Jun; 37(12):1758-68. PubMed ID: 8021916
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of highly potent HIV-1 protease inhibitors with novel isosorbide-derived P2 ligands.
Qiu X; Zhao GD; Tang LQ; Liu ZP
Bioorg Med Chem Lett; 2014 Jun; 24(11):2465-8. PubMed ID: 24767846
[TBL] [Abstract][Full Text] [Related]
14. Structure-based design, synthesis, X-ray studies, and biological evaluation of novel HIV-1 protease inhibitors containing isophthalamide-derived P2-ligands.
Ghosh AK; Takayama J; Kassekert LA; Ella-Menye JR; Yashchuk S; Agniswamy J; Wang YF; Aoki M; Amano M; Weber IT; Mitsuya H
Bioorg Med Chem Lett; 2015 Nov; 25(21):4903-4909. PubMed ID: 26096678
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological evaluation of novel HIV-1 protease inhibitors using tertiary amine as P2-ligands.
Yang ZH; Bai XG; Zhou L; Wang JX; Liu HT; Wang YC
Bioorg Med Chem Lett; 2015 May; 25(9):1880-3. PubMed ID: 25838144
[TBL] [Abstract][Full Text] [Related]
16. Cyclic HIV protease inhibitors: design and synthesis of orally bioavailable, pyrazole P2/P2' cyclic ureas with improved potency.
Han Q; Chang CH; Li R; Ru Y; Jadhav PK; Lam PY
J Med Chem; 1998 Jun; 41(12):2019-28. PubMed ID: 9622543
[TBL] [Abstract][Full Text] [Related]
17. Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor.
Surleraux DL; Tahri A; Verschueren WG; Pille GM; de Kock HA; Jonckers TH; Peeters A; De Meyer S; Azijn H; Pauwels R; de Bethune MP; King NM; Prabu-Jeyabalan M; Schiffer CA; Wigerinck PB
J Med Chem; 2005 Mar; 48(6):1813-22. PubMed ID: 15771427
[TBL] [Abstract][Full Text] [Related]
18. Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors.
Lam PY; Jadhav PK; Eyermann CJ; Hodge CN; Ru Y; Bacheler LT; Meek JL; Otto MJ; Rayner MM; Wong YN
Science; 1994 Jan; 263(5145):380-4. PubMed ID: 8278812
[TBL] [Abstract][Full Text] [Related]
19. Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy.
Kempf DJ; Sham HL; Marsh KC; Flentge CA; Betebenner D; Green BE; McDonald E; Vasavanonda S; Saldivar A; Wideburg NE; Kati WM; Ruiz L; Zhao C; Fino L; Patterson J; Molla A; Plattner JJ; Norbeck DW
J Med Chem; 1998 Feb; 41(4):602-17. PubMed ID: 9484509
[TBL] [Abstract][Full Text] [Related]
20. Structure-activity relationships of novel HIV-1 protease inhibitors containing the 3-amino-2-chlorobenzoyl-allophenylnorstatine structure.
Mimoto T; Nojima S; Terashima K; Takaku H; Shintani M; Hayashi H
Bioorg Med Chem; 2008 Feb; 16(3):1299-308. PubMed ID: 17981045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
